quantisnow
FeedTopReportsPricing
⌘K
Live feed
12:49:56·43d
INSIDERFiling
Aquestive Therapeutics Inc. logo

Chief Development Officer Davis Matthew W. was granted 50,000 shares, increasing direct ownership by 100% to 100,000 units (SEC Form 4)

AQST· Aquestive Therapeutics Inc.
Health Care
Original source

Companies

  • AQST
    Aquestive Therapeutics Inc.
    Health Care

Recent analyst ratings

  • Apr 24UpdateOppenheimer$8.00
  • Jun 2UpdateOppenheimer$7.00
  • Dec 17UpdateCantor Fitzgerald$17.00
  • May 10UpdateLeerink Partners$8.00
  • Apr 11UpdatePiper Sandler$10.00
  • Mar 28UpdateRaymond James$7.00

Related

  • ANALYST1h
    Oppenheimer resumed coverage on Aquestive Therapeutics with a new price target
  • INSIDER10d
    SEC Form 4 filed by Barber Daniel
  • INSIDER10d
    SEC Form 4 filed by Boyd Peter E.
  • INSIDER10d
    SEC Form 4 filed by Jung Cassie
  • INSIDER10d
    SEC Form 4 filed by Toth A Ernest Jr
  • INSIDER10d
    SEC Form 4 filed by Korczynski Sherry
  • INSIDER10d
    SEC Form 4 filed by Braender Lori J
  • INSIDER13d
    SEC Form 3 filed by new insider Zalewski Thomas A.
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022